Author:
Li Kevin,Lee Andrew,Abuzeid Waleed
Abstract
The correlation between aspirin sensitivity, asthma, and nasal polyposis was recognized in the early 20th century. Today, this classic triad of symptoms, eponymously named Samter’s Triad, is known as aspirin exacerbated respiratory disease (AERD). Aspirin exacerbated respiratory disease affects approximately 0.3–0.9% of the general population in the USA and approximately 7% of asthmatic patients. The management of AERD is challenging as no single modality has proven to have high rates of symptom control. Consequently, disease management typically involves a multimodality approach across both medical and surgical disciplines. This review describes the epidemiology of AERD and the current state-of-the-art as it relates to the underlying pathophysiologic mechanisms of this disease process. A significant proportion of the review is focused on the appropriate diagnostic workup for AERD patients including the utility of aspirin provocation testing. The spectrum of medical treatments, including aspirin desensitization and recently introduced immunotherapies, are discussed in detail. Furthermore, surgical approaches to disease control, including advanced endoscopic techniques, are reviewed and treatment outcomes presented.
Subject
General Economics, Econometrics and Finance
Reference103 articles.
1. First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria)--1922 (with a note on aspirin desensitization);Widal;J. Asthma,1987
2. Intolerance to Aspirin
3. Aspirin-exacerbated respiratory disease and current treatment modalities
4. Samter’s Triad: State of the Art
5. Natural history of aspirin-induced asthma
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献